Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Directory
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Immuno-oncology Therapies
Sort By
Newest First
1 / 2
1 / 2
Immuno-oncology
Activating the Immune System to Treat Cancer
Heat Biologics
PAO-01-22-R250-06
Jan 26, 2022
Cell Therapy
Economically Viable, Same-Day Autologous Cell Therapies
Gregory Frost, Ph.D.; Sid Kerkar, M.D.
EXUMA Biotechnology
PAO-01-21-CL-06
Feb 04, 2021
M&A
Astellas Strengthens Immuno-oncology Pipeline with Acquisition of Xyphos Biosciences, Inc.
Astellas
PR-M01-20-NI-006
Jan 03, 2020
Immunotherapy
Collaborating for Immunotherapy Development
KshitiJ (TJ) Ladage
Nice Insight
PAP-Q1-2019-NI-007
Mar 12, 2019
Immuno-oncology
Sanofi and Regeneron Immuno-oncology Collaboration Ending
Nice Insight
PAO-M01-19-NI-012
Jan 09, 2019
Immuno-Oncology
FIMECS, Inc. Concludes Licensing Agreement with Takeda to Develop Novel Immuno-Oncology Therapies
FIMECS, Inc.
PR-M04-18-NI-44
Apr 13, 2018
Immuno-oncology
Allogene Therapeutics Completes Agreement for Pfizer’s Allogeneic CAR T Immuno-oncology Portfolio
Allogene Therapeutics
PR-M04-18-NI-40
Apr 12, 2018
Immuno-Oncology
Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership
Boehringer Ingelheim
PR-M04-18-NI-030
Apr 10, 2018
Immuno-Oncology
European Commission Approves Bristol-Myers Squibb’s Yervoy (ipilimumab) for Treatment of Pediatric Patients 12 Years and Older with Unresectable or Metastatic Melanoma
Bristol-Myers Squibb
PR-M01-18-NI-082
Jan 25, 2018
Acquisition
Charles River Laboratories Continues to Grow Through Acquisition
Nigel Walker
Nice Insight
PAO-M01-18-NI-035
Jan 19, 2018
Drug Development
Potenza Therapeutics Unveils Pipeline of Immuno-Oncology Programs
Potenza Therapeutics, Inc.
PR-M01-18-NI-024
Jan 10, 2018
Business
Cue Biopharma Announces Closing of Initial Public Offering
Cue Biopharma
PR-M01-18-NI-003
Jan 02, 2018
Immuno-Oncology Therapies
ARMO BioSciences Files Registration Statement for Proposed Initial Public Offering
ARMO BioSciences, Inc
PR-M01-18-NI-001
Jan 02, 2018
Drug Development
Memory T Cells Fit to be Cross Trained
Nice Insight
PAO-M12-17-NI-027
Dec 19, 2017
Oncology
Altering White Blood Cells to Kill Cancer
Nigel Walker
Nice Insight
PAO-M12-17-NI-026
Dec 19, 2017
Innovation
Bristol-Myers Squibb Granted Exclusive License by Ono Pharmaceutical for Multiple Programs Targeting Immuno-Suppressive Factors in the Tumor Microenvironment
Bristol-Myers Squibb
PR-M12-17-NI-015
Dec 15, 2017
Immuno-oncology
Genentech and Biothera to Assess Combination Cancer Therapy
Nice Insight
PAO-M12-17-NI-010
Dec 08, 2017
Immuno-oncology
Immuno-oncology Approach Based on Electronic Circuitry
Guy Tiene
Nice Insight
PAO-M11-17-NI-008
Nov 03, 2017
Oncology
Bristol-Myers Squibb Will Acquire IFM Therapeutics’ Innate Immune System Stimulators
Nice Insight
PAO-M08-17-NI-015
Aug 11, 2017
Drug Development
New Partnership Targets Colorectal Cancer with Combination Therapy, Including Avelumab
Guy Tiene
Nice Insight
PAO-M06-17-NI-020
Jun 29, 2017
